Keywords: Sinclair, Solvay, Flammazine, Flammacerium, Licensing, Management
Sinclair buys Flammazine and Flammacerium from Solvay for $25.9 million
Article | 13 October 2009
UK specialty drugmaker Sinclair Pharma has acquired two major revenue-generating dermatology products for a total consideration of 17.5 million euros ($25.9 million) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
